Status:
COMPLETED
Alefacept for Chronic Graft Versus Host Disease
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Resistant Chronic GVHD
Eligibility:
All Genders
Up to 70 years
Phase:
PHASE1
PHASE2
Brief Summary
Alefacept (AMEVIVE®) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fcof IgG1. Al...
Eligibility Criteria
Inclusion
- No age limit
- Resistant chronic GVHD
Exclusion
- Not fulfilling any of the inclusion criteria
- Active life-threatening infection
- Inability to comply with study requirements.
- Known hypersensitivity to alefacept.
- Active malignant disease
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00397332
Start Date
October 1 2006
End Date
July 1 2013
Last Update
April 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Stem cell Transplantation & Cancer immunotherapy; Cell Therapy & Transplantation Biology Research Laboratory, Hadassah University Hospital
Jerusalem, Israel, 91120